Beijing Strong BiotechnologiesInc Past Earnings Performance
Past criteria checks 5/6
Beijing Strong BiotechnologiesInc has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 18.4% per year. Beijing Strong BiotechnologiesInc's return on equity is 13.9%, and it has net margins of 30.3%.
Key information
14.6%
Earnings growth rate
10.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 18.4% |
| Return on equity | 13.9% |
| Net Margin | 30.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Strong BiotechnologiesInc makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,762 | 533 | 501 | 170 |
| 31 Dec 23 | 1,742 | 524 | 499 | 163 |
| 30 Sep 23 | 1,622 | 491 | 466 | 142 |
| 30 Jun 23 | 1,615 | 468 | 493 | 147 |
| 31 Mar 23 | 1,512 | 402 | 475 | 142 |
| 31 Dec 22 | 1,511 | 389 | 475 | 137 |
| 30 Sep 22 | 1,504 | 364 | 480 | 145 |
| 30 Jun 22 | 1,504 | 347 | 486 | 136 |
| 31 Mar 22 | 1,598 | 392 | 485 | 133 |
| 01 Jan 22 | 1,599 | 406 | 463 | 127 |
| 30 Sep 21 | 1,539 | 335 | 488 | 111 |
| 30 Jun 21 | 1,391 | 299 | 408 | 100 |
| 31 Mar 21 | 1,109 | 212 | 321 | 88 |
| 31 Dec 20 | 848 | 112 | 272 | 79 |
| 30 Sep 20 | 797 | 202 | 177 | 77 |
| 30 Jun 20 | 752 | 234 | 137 | 72 |
| 31 Mar 20 | 781 | 284 | 137 | 69 |
| 31 Dec 19 | 841 | 332 | 136 | 70 |
| 30 Sep 19 | 813 | 324 | 131 | 66 |
| 30 Jun 19 | 787 | 318 | 132 | 65 |
| 31 Mar 19 | 783 | 303 | 132 | 63 |
| 31 Dec 18 | 774 | 301 | 131 | 61 |
| 30 Sep 18 | 755 | 285 | 133 | 61 |
| 30 Jun 18 | 748 | 279 | 104 | 84 |
| 31 Mar 18 | 718 | 280 | 109 | 69 |
| 31 Dec 17 | 694 | 273 | 121 | 54 |
| 30 Sep 17 | 657 | 266 | 129 | 37 |
| 30 Jun 17 | 660 | 259 | 161 | 0 |
| 31 Mar 17 | 658 | 259 | 160 | 0 |
| 31 Dec 16 | 667 | 272 | 150 | 0 |
| 30 Sep 16 | 646 | 266 | 142 | 0 |
| 30 Jun 16 | 595 | 259 | 134 | 0 |
| 31 Mar 16 | 590 | 255 | 126 | 0 |
| 31 Dec 15 | 566 | 245 | 124 | 0 |
| 30 Sep 15 | 548 | 222 | 126 | 0 |
| 30 Jun 15 | 543 | 218 | 127 | 0 |
| 31 Mar 15 | 524 | 218 | 120 | 0 |
| 31 Dec 14 | 508 | 211 | 119 | 0 |
| 30 Sep 14 | 480 | 205 | 107 | 0 |
| 31 Dec 13 | 445 | 181 | 91 | 0 |
Quality Earnings: 300406 has high quality earnings.
Growing Profit Margin: 300406's current net profit margins (30.3%) are higher than last year (26.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300406's earnings have grown by 14.6% per year over the past 5 years.
Accelerating Growth: 300406's earnings growth over the past year (32.7%) exceeds its 5-year average (14.6% per year).
Earnings vs Industry: 300406 earnings growth over the past year (32.7%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 300406's Return on Equity (13.9%) is considered low.